Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Feb 9, 2016
Grant Date -
Nov 7, 2013
app pub date -
May 7, 2013
filing date -
May 7, 2012
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly FGFR2 variants, which are linked to drug resistance. The disclosure further provides methods of diagnosis and theranosis, using these molecules and fragments thereof, and kits for employing these methods and compositions.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully